Table 1 Demographic and clinical characteristics of patients in the training and validation cohorts
From: Development and validation of prognostic nomograms for patients with colon neuroendocrine neoplasms
Variable | Training cohort (n = 896) | Validation cohort (n = 300) | Total (n = 1196) | P value |
|---|---|---|---|---|
Median age, years | 61.8 ± 13.0 | 62.3 ± 13.1 | 61.9 ± 13.1 | 0.599 |
Age, years | 0.666 | |||
0–55 | 33.8% (303/896) | 31% (93/300) | 33.1% (396/1196) | |
56–67 | 33.8% (303/896) | 35% (105/300) | 34.1% (408/1196) | |
≥ 68 | 32.4% (290/896) | 34% (102/300) | 32.8% (392/1196) | |
Sex | 0.919 | |||
Female | 51.7% (463/896) | 51.3% (154/300) | 51.6% (617/1196) | |
Male | 48.3% (433/896) | 48.7% (146/300) | 48.4% (579/1196) | |
Median tumor diameter, mm | 40.5 ± 28.1 | 42.6 ± 38.7 | 41 ± 31.1 | 0.3 |
Tumor size, mm | 0.843 | |||
< 35 | 48.3% (433/896) | 47.7% (143/300) | 48.2% (576/1196) | |
≥ 35 | 51.7% (463/896) | 52.3% (157/300) | 51.8% (620/1196) | |
Laterality | 0.812 | |||
Right | 76.7% (687/896) | 76% (228/300) | 76.5% (915/1196) | |
Left | 23.3% (209/896) | 24% (72/300) | 23.5% (281/1196) | |
Grade | 0.031 | |||
G1 | 39.8% (357/896) | 39.7% (119/300) | 39.8% (476/1196) | |
G2 | 15.5% (139/896) | 17.7% (53/300) | 16.1% (192/1196) | |
G3 | 30.9% (277/896) | 23.7% (71/300) | 29.1% (348/1196) | |
G4 | 13.7% (123/896) | 19% (57/300) | 15.1% (180/1196) | |
Pathology | 0.006 | |||
8013/3 large cell neuroendocrine carcinoma | 7.5% (67/896) | 7.7% (23/300) | 7.5% (90/1196) | |
8041/3 small cell carcinoma | 4.1% (37/896) | 3.3% (10/300) | 3.9% (47/1196) | |
8240/3 carcinoid tumor | 37.9% (340/896) | 34.7% (104/300) | 37.1% (444/1196) | |
8244/3 mixed adeno-neuroendocrine carcinoma | 3.8% (34/896) | 9.3% (28/300) | 5.2% (62/1196) | |
8246/3 neuroendocrine carcinoma | 46.7% (418/896) | 45% (135/300) | 46.2% (553/1196) | |
Operation | 0.864 | |||
No operation | 3.7% (33/896) | 3.3% (10/300) | 3.6% (43/1196) | |
Local tumor excision | 8.5% (76/896) | 7.7% (23/300) | 8.3% (99/1196) | |
Curative | 87.8% (787/896) | 89% (267/300) | 88.1% (/1196) | |
Chemotherapy | 0.82 | |||
No | 72% (645/896) | 72.7% (218/300) | 72.2% (863/1196) | |
Yes | 28% (251/896) | 27.3% (82/300) | 27.8% (333/1196) | |
AJCC TNM stage (8th) | 0.337 | |||
I | 12.2% (109/896) | 10.3% (31/300) | 11.7% (140/1196) | |
IIA | 2.6% (23/896) | 1.7% (5/300) | 2.3% (28/1196) | |
IIB | 6.5% (58/896) | 9.3% (28/300) | 7.2% (86/1196) | |
IIIA | 1.2% (11/896) | 2% (6/300) | 1.4% (17/1196) | |
IIIB | 42% (376/896) | 44% (132/300) | 42.5% (508/1196) | |
IV | 35.6% (319/896) | 32.7% (98/300) | 34.9% (417/1196) | |
AJCC T stage (8th) | 0.066 | |||
T1 | 0.6% (5/896) | 0.7% (2/300) | 0.6% (7/1196) | |
T1a | 10.7% (96/896) | 9.3% (28/300) | 10.4% (124/1196) | |
T1b | 3.7% (33/896) | 2.3% (7/300) | 3.3% (40/1196) | |
T2 | 11.6% (104/896) | 8% (24/300) | 10.7% (128/1196) | |
T3 | 49.9% (447/896) | 48% (144/300) | 49.4% (591/1196) | |
T4 | 23.5% (211/896) | 31.7% (95/300) | 25.6% (306/1196) | |
AJCC N stage (8th) | 0.968 | |||
N0 | 26.8% (240/896) | 26.7% (80/300) | 26.8% (320/1196) | |
N1 | 73.2% (656/896) | 73.3% (220/300) | 73.2% (876/1196) | |
AJCC M stage (8th) | 0.356 | |||
M0 | 64.4% (577/896) | 67.3% (202/300) | 65.1% (779/1196) | |
M1 | 35.6% (319/896) | 32.7% (98/300) | 34.9% (417/1196) | |
OS | 0.897 | |||
Alive | 53.2% (477/896) | 53.7% (161/300) | 53.3% (638/1196) | |
Dead | 46.8%(419/896) | 46.3% (139/300) | 46.7% (558/1196) | |
CSS | 0.441 | |||
Alive | 60.2% (539/896) | 62.7% (188/300) | 60.8% (727/1196) | |
Dead due to cancer | 39.8% (357/896) | 37.3% (112/300) | 39.2% (469/1196) | |
Survival, months | 38.8 ± 37.1 | 38.8 ± 37.1 | 38.9 ± 36.3 | 0.866 |